Quanterix (NASDAQ:QTRX) announced its quarterly earnings results on Wednesday. The company reported ($0.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.04), reports.
Shares of Quanterix (NASDAQ:QTRX) traded down $0.19 during mid-day trading on Wednesday, reaching $20.63. 194,879 shares of the company traded hands, compared to its average volume of 118,886. Quanterix has a 12 month low of $15.56 and a 12 month high of $24.81.
Several analysts have issued reports on the stock. BTIG Research assumed coverage on shares of Quanterix in a research note on Tuesday, January 2nd. They issued a “buy” rating and a $26.00 price objective for the company. JPMorgan Chase & Co. started coverage on shares of Quanterix in a research note on Tuesday, January 2nd. They issued an “overweight” rating for the company. Leerink Swann assumed coverage on shares of Quanterix in a research report on Tuesday, January 2nd. They set an “outperform” rating and a $27.00 target price on the stock. Finally, Cowen assumed coverage on shares of Quanterix in a research report on Tuesday, January 2nd. They set an “outperform” rating on the stock.
TRADEMARK VIOLATION NOTICE: “Quanterix (QTRX) Posts Earnings Results, Misses Estimates By $0.04 EPS” was posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.thelincolnianonline.com/2018/03/14/quanterix-qtrx-posts-earnings-results-misses-estimates-by-0-04-eps.html.
Quanterix Company Profile
Quanterix Corporation is a United States-based company, which develops tools for high definition diagnostics. The Company offers single molecule array (Simoa) platform, which uses single molecule measurements to access proteins. Simoa focuses on research and clinical testing applications. The Company focuses on research and diagnostics for brain injuries, heart disease, cancer and other diseases with its technology.
Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.